Charles Morris

Charles Morris

Direttore Tecnico/Scientifico/R&S presso PRELUDE THERAPEUTICS INCORPORATED
61 anni
Health Technology
Consumer Services

Profilo

Charles Q.
Morris
is currently a Member at The Royal College of Physicians and Chief Medical Officer at Prelude Therapeutics, Inc. starting in 2026.
Former positions include Vice President-Worldwide Clinical Research at Cephalon, Inc., Chief Development Officer & Executive VP at ImmunoGen, Inc. from 2012 to 2016, Chief Medical Officer & Executive Vice President at Allos Therapeutics, Inc. from 2010 to 2012, Chief Medical Officer at Radius Health, Inc. from 2018 to 2020, Vice President-Clinical Development Projects at AstraZeneca Pharmaceuticals LP, Chief Development Officer at Akamis Bio Ltd. from 2016 to 2018, and Chief Medical Officer at Celyad Oncology SA from 2021 to 2023.
Education includes undergraduate studies at the University of Sheffield Medical School.

Posizioni attive di Charles Morris

SocietàPosizioneInizio
PRELUDE THERAPEUTICS INCORPORATED Direttore Tecnico/Scientifico/R&S 20/04/2026
Corporate Officer/Principal 09/07/2010

Precedenti posizioni note di Charles Morris

SocietàPosizioneFine
LAVA THERAPEUTICS N.V. Direttore Tecnico/Scientifico/R&S 01/10/2025
CELYAD ONCOLOGY SA Direttore Tecnico/Scientifico/R&S 01/01/2023
RADIUS HEALTH, INC. Direttore Tecnico/Scientifico/R&S 15/12/2020
Corporate Officer/Principal 01/09/2018
IMMUNOGEN, INC. Corporate Officer/Principal 02/09/2016
Vedi nel dettaglio l'esperienza di Charles Morris

Formazione di Charles Morris

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

63

Relazioni di 1° grado

11

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private11

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

  1. Mercati
  2. Insiders
  3. Charles Morris
ULTIMI ORARI | -40%: I migliori strumenti riservati agli abbonati per identificare i migliori investimenti di domani!
g
:
:
ENTRA ORA